Heyholder
‹ Activism Filings

CKD Bio Corp. Q3 operating loss of KRW 5.9 billion on KRW 29.3 billion in sales

CKD Bio Corp.· Periodic Report

AI summary · Not investment advice

In Q3, the company sold KRW 29.3 billion worth and lost KRW 5.9 billion from its main business; sales fell 14.0% from a year earlier and 28.6% from the prior quarter.

Operating profit · 3 months

KRW -6.0 billion

Key facts

Revenue (3 months)
KRW 29.3 billion
Net income (3 months)
KRW -10.5 billion
Period
Q3 (cumulative 2026.01.01 ~ 2026.09.30)
Revenue (prior-year 3 months)
KRW 34.1 billion
Revenue (year to date)
KRW 111.1 billion
Operating profit (prior-year 3 months)
KRW -1.5 billion
Operating profit (year to date)
KRW -12.7 billion
Net income (prior-year 3 months)
KRW -2.2 billion
Net income (year to date)
KRW -17.9 billion

Commentary

AI commentary · Not investment advice

What happened

Jongkundang Bio reported its standalone results for the 3rd quarter of 2026. Sales for the 3 months were KRW 29.33 billion. That is 14.0% lower than the same 3 months a year earlier (KRW 34.12 billion) and 28.6% lower than the previous quarter.

In the company's terms

Operating profit (profit from the core business) for the 3 months was a loss of KRW 5.99 billion. A year earlier it was a loss of KRW 1.47 billion. Net income (the final profit after taxes and other costs) for the 3 months was a loss of KRW 10.48 billion. A year earlier it was a loss of KRW 2.18 billion.

What changes for shareholders

For the cumulative period from January to September, sales were KRW 111.11 billion. Operating profit was a loss of KRW 12.70 billion. Net income was a loss of KRW 17.92 billion.

Comments

No comments yet

Comments from shareholders will appear here.